title: [Preventive treatment of migraine with vasobral: a multicenter trial].
abstract: The results of an open prospective trial on the treatment of migraine with vasobral which was conducted in 170 medical centers (27 cities) of the Russian Federation are summarized. The trial included 5475 patients treated with vasobral in dosage 2 ml (1 ml contains 1 mg of alpha-dihydroergocryptine and 10 mg of caffeine) twice a day during 2 months. Assessment criteria of treatment efficacy were frequency and duration of migraine seizures, pain syndrome severity, presence of concomitant syndromes, general state and working capacity of patients and side-effects. Vasobral was effective and safe medication for the prevention of migraine. Its preventive effect is due to the decrease of frequency and duration of migraine seizures, pain severity and to the overall improvement of patient's state. Vasobral can be recommended to many migraine patients, in particular to those in the young age and with short disease duration.
authors.forename: G R
authors.initials: GR
authors.lastname: Tabeeva
authors.forename: Iu E
authors.initials: IuE
authors.lastname: Azimova
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002110:Caffeine / Q000627:therapeutic use*; D004088:Dihydroergotoxine / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000503:physiopathology / Q000517:prevention & control*; D011446:Prospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D004088:Dihydroergotoxine; D002110:Caffeine; C055581:Vasobral